NBSE Stock Price History and Quote Analysis Insights for Investors
NeuBase Therapeutics, Inc.
Stock Price Today
NeuBase Therapeutics, Inc. (NBSE) stock declined over -1.56%, trading at $0.38 on NASDAQ, down from the previous close of $0.38. The stock opened at $0.38, fluctuating between $0.37 and $0.39 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Company Information
| Employees | 37 |
| Beta | 0.94 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | September |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
NeuBase Therapeutics, Inc. (NASDAQ: NBSE) stock price is $0.38 in the last trading session. During the trading session, NBSE stock reached the peak price of $0.39 while $0.37 was the lowest point it dropped to. The percentage change in NBSE stock occurred in the recent session was -1.56% while the dollar amount for the price change in NBSE stock was -$0.01.
The NASDAQ listed NBSE is part of Biotechnology industry that operates in the broader Healthcare sector. NeuBase Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Todd P. Branning
Chief Financial Officer & Sec.
Dr. Robert J. Zamboni Ph.D.
Chief of Preclinical Devel. & Member of Scientific Advisory Board
Dr. Dietrich A. Stephan Ph.D.
Founder, Chief Executive Officer, Pres & Director
Dr. Curt Bradshaw Ph.D.
Chief Scientific Officer
Ms. Shannon McCarthy
Chief People Officer
Dr. Ron Sarkar M.B.A., Ph.D.
Senior Vice President of Corporation Strategy & Bus. Devel.
Mr. Alan Scrivner J.D.
Gen. Counsel
NBSE's closing price is 5% higher than its 52-week low of $0.36 where as its distance from 52-week high of $4.44 is -91.49%.
Number of NBSE employees currently stands at 37.
Official Website of NBSE is: https://www.neubasetherapeutics.com
NBSE could be contacted at phone 646 450 1790 and can also be accessed through its website. NBSE operates from 350 Technology Drive, Pittsburgh, PA 15219, United States.
NBSE stock volume for the day was 89.7K shares. The average number of NBSE shares traded daily for last 3 months was 128.24K.
The market value of NBSE currently stands at $1.42M with its latest stock price at $0.38 and 3.75M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com